The MIND Diet for Breast Cancer Cognition (MIND-BC) Study
This study, called MIND-BC, is looking at whether the MIND Diet can help improve thinking and memory problems (cognition) in women who have had breast cancer. The MIND Diet combines elements of the Mediterranean and DASH diets, focusing on healthy foods like leafy greens, berries, fish, and olive oil, while limiting unhealthy fats and processed foods. You might be able to join if you are a woman over 18, have been diagnosed with stage I-III breast cancer, and have recently completed your breast cancer treatment (6 months to 3 years ago). We are looking for 200 participants. The main goal is to see if the MIND Diet improves self-reported thinking and memory after 12 weeks and 3 months.
- Study design
- This study is a randomized controlled trial, meaning participants will be randomly assigned to either follow the MIND Diet or their usual diet. It plans to enroll 200 women.
- What's involved
- The study involves two 12-week phases: an intervention phase and a maintenance phase. Check-in sessions for the usual diet group will focus on general health, not diet.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants' self-reported cognition will be measured at 12 weeks and 3 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
The MIND-BC Study: MIND Diet for Breast Cancer Cognition
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Sylvia Crowder · PRINCIPAL_INVESTIGATOR · Moffitt Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Efficacy of the MIND diet: Self-reported cognitionAt 12 weeks and 3 months
The Functional Assessment of Cancer Therapy - General (FACT-G) will be used to determine self-reported cognition.